Navigation Links
Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
Date:10/19/2008

Non-surgical intervention cures 96% of patients with advanced esophagus

condition

SUNNYVALE, Calif., Oct. 19 /PRNewswire/ -- BARRX Medical, Inc. today announced clinical trial results presented at the United European Gastroenterology Week (UEGW) in Vienna, Austria, October 18-22, 2008. In a plenary presentation entitled, "Stepwise circumferential and focal radiofrequency energy ablation of Barrett's esophagus with early neoplasia: First European Multi-centre trial" patients with the most advanced stages of Barrett's esophagus, dysplasia and early cancer, were staged with endoscopic mucosal resection and then treated with the endoscopic radiofrequency ablation using the HALO Ablation System. After treatment, 96% of patients were cured of all diseased tissue, with average follow-up exceeding one year.

Population-based studies estimate that Barrett's esophagus affects approximately six million European and US adults and is a complication of a disorder called gastroesophageal reflux disease or GERD. Once diagnosed, Barrett's can worsen over time, developing dysplasia and esophageal adenocarcinoma (cancer), as in this study. Once dysplasia or cancer occurs, an esophagectomy (surgical removal of the entire esophagus) has been the first-line therapy. Esophageal cancer of this type is the fastest growing cancer in industrialized countries.

Jacques Bergman, M.D., Associate Professor, Department of Gastroenterology, Academic Medical Centre, Amsterdam, the Netherlands, was the senior investigator for this study. "In several back to back studies now, we have been successful in using the HALO Ablation System in conjunction with endoscopic resection to cure patients with advanced dysplasia or early cancer of the esophagus," says Dr. Bergman. "Until now, these patients would receive an esophagectomy or more invasive endoscopic therapies, which often have associated safety risks. In this study, the complete response rate was quite high, over 95%."

In this study, patients with the most advanced stages of Barrett's esophagus (dysplasia and early cancer) were first staged with endoscopic resection where a large tissue biopsy was obtained to confirm absence of deeply invasive cancer. The patient then received ablation using the HALO360 Ablation System, a balloon-based ablation device designed to remove the diseased cells using controlled heat. Procedures were performed non-surgically, using endoscopy and sedation, which allowed the patient to return to normal activity after the procedure. Patients then underwent focal ablation with the HALO90 Ablation System, a smaller device that mounts on the endoscope and is designed to treat small residual areas of Barrett's esophagus. Patients had endoscopy with biopsy to confirm elimination of the disease.

The study was conducted at three European centres, including the Academic Medical Centre, Amsterdam; Evangelisches Krankenhaus, Dusseldorf; and Erasme University Hospital, Brussels.

About the United European Gastroenterology Week (UEGW)

The UEGW is sponsored by the United European Gastroenterology Federation and is the venue where scientists and clinicians present and learn about the latest advances in the fields of gastroenterology, endoscopy, hepatology, and gastrointestinal surgery.

About BARRX Medical, Inc.

BARRX Medical, Inc. develops non-surgical, endoscopic treatment solutions for Barrett's esophagus. The company's HALO360 Ablation System uses a balloon-based electrode to ablate Barrett tissue circumferentially within the esophagus. The HALO90 Ablation System is an electrode system that is mounted on the end of an endoscope, allowing the physician to treat focal areas of diseased tissue. Both HALO Systems provides uniform and controlled therapy at a consistent depth to remove Barrett's esophagus and allow the regrowth of normal cells. Both systems are cleared by the U.S. Food and Drug Administration and have CE Mark in Europe. Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is a privately held company. Additional information about BARRX Medical, Inc. and the HALO System is available at http://www.barrx.com.


'/>"/>
SOURCE BARRX Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
4. First European Patients Treated With the Percutaneous MitraClip(R) System
5. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
6. Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
9. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
10. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
11. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... ... Forecast 2016-2026: Opportunities for Leading Companies – our new ... new report discusses issues and events affecting the Alzheimer,s ... qualitative analyses to answer these key questions: - How ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... 2017 Accuray Incorporated (Nasdaq: ARAY ... continue to set the bar for excellence in customer ... user satisfaction rating among radiation treatment delivery systems in ... Market Intelligence Briefing™. The most recent ratings trend also ... industry peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Knowledge is ... be guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, ... cookbooks, novels, and poetry collections. , “I have been writing since high school ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO ... the name of their drug rehab center in Delray Beach, Florida has been changed ... not only stars such as Philip Seymour Hoffman and Chris Farley are dying from ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Cosmetic ... of plastic surgery procedures in order to make it easier for their readers to ... of the body they impact as well as the techniques used on those particular ...
(Date:1/19/2017)... IL (PRWEB) , ... January 19, 2017 , ... ... N.A., announced it recently provided a new $11,250,000 senior credit facility to Sunrise, ... new MB credit facility were used to facilitate a recapitalization of MedPro led ...
Breaking Medicine News(10 mins):